Master ReVasca Monograph 6.2.24 - Paper - Page 3
REVASCA™ PHYSICIAN MONOGRAPH
— Background – What is the Glycocalyx? — (cont.)
and chronic kidney disease (CKD) among others.
What degrades the endothelial glycocalyx (eGCX)? Many
factors can cause damage to the eGCX, including:
•
•
•
•
•
•
•
•
•
•
•
•
Aging
Chronic stress
Poor diet – high carb, high sugar/ high glycemic
Lack or exercise OR over-exercising
Genetics
Sepsis
GUT/microbiome disruption (dysbiosis) and leaky GUT
syndrome
Chronic and high levels of oxidative stress such as with
environmental contaminants like heavy metal intoxication, pesticides, smoking
Insulin resistance / T2D
Viral infections - including SARS-Cov-2 (COVID-19)
CKD is a major independent risk factor for cardiovascular
disease (CVD).8 Patients with Chronic Kidney Disease
(CKD) have a very high risk of cardiovascular disease and
premature death when they need to be treated with
hemodialysis to detoxify their blood when their kidneys
are failing. The toxins in the blood of hemodialysis CKD
patients damage their blood vessels, and many recent
studies have demonstrated that the increased cardiovascular risk is associated with damage of the eGCX.9
Endothelial cells and the glycocalyx play a crucial role in
the development and propagation of the severe COVID-19
stage as well as multiorgan dysfunction. Studies report the
crucial role of the endothelial glycocalyx in the regulation
of the S-protein (spike protein) binding to ACE2 receptors
on endothelial cells.
Reduction of the glycocalyx layer exposes ACE2 receptors
and promotes their interaction with S-protein, indicating
that the susceptibility of endothelial cells to COVID-19
infection may depend on the glycocalyx condition. 10
Preserving the eGCX should be of paramount importance
for clinicians treating COVID-19 patients, both active
infection and post-infection. SARS-CoV-2 infection is
reported to degrade the eGCX. 11
Studies report that the endothelial glycocalyx is a viable
therapeutic target to slow down age-related vascular
dysfunction.12 But what choices do clinicians have to
protect the eGCX? Clinicians have used pharmaceuticals
such as hydrocortisone, heparin, dexamethasone, and
doxycycline. But recently, scientists that were involved in
the initial research on human endothelial glycocalyx have
developed an all-natural nutraceutical that supports a
healthy glycocalyx - ReVasca™.
ReVasca™ is the most powerful formula to date designed
to restore and protect the endothelial glycocalyx.